Filing Details

Accession Number:
0001179110-11-004058
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-03-03 16:30:21
Reporting Period:
2011-03-01
Filing Date:
2011-03-03
Accepted Time:
2011-03-03 16:30:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1157601 Synta Pharmaceuticals Corp SNTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1325714 E Wendy Rieder C/O Synta Pharmaceuticals Corp.
45 Hartwell Avenue
Lexington MA 02421
Vp, Ip And Legal, Gen. Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-03-01 5,284 $5.25 15,426 No 4 S Direct
Common Stock Acquisiton 2011-03-01 4,397 $0.00 19,823 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Acquisiton 2011-03-01 41,891 $0.00 41,891 $5.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
41,891 2021-03-01 No 4 A Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2010, and were made in part to fund certain out-of-pocket tax withholding liabilities associated with the vesting of restricted stock granted on March 1, 2010.
  2. The shares were sold in multiple transactions at prices ranging from $5.25 to $5.33 per share. The price reported above is the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 100% of the shares on March 1, 2012, provided the Reporting Person remains employed by the Issuer on such date.
  4. The option vests as to 25% of the shares on March 1, 2012 and as to an additional 6.25% of the shares on the last day of each successive three-month period thereafter.